This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
GYPA · Western blot design guide
GYPA Western Blot Planning Guide
Plan a GYPA Western blot around the catalog-observed 16.4 kDa band, image-backed A02184-2 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
GYPA Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 16.4 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 15% | |
| Positive control | Kidney | |
| Negative control | Adipose tissue |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 16.4 kDa |
| ⓘ | Localization | Cell membrane |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human |
Sample controls for GYPA Western blot
🧪Use Kidney as the first positive-control candidate and Adipose tissue as the HPA Not detected negative candidate.
Positive control: Kidney (Medium)
Negative control: Adipose tissue (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for GYPA
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart on each tissue page — click any row's HPA link to view the source.
Section 1
What Is the Expected GYPA Western Blot Band Size?
Use the product-observed 16.4 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 16.4 kDa | Matches the authoritative product WB observation. |
| 16.4 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected GYPA appearancePlan around 16.4 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 16.4 kDa; use this as the primary experimental expectation. |
| Calculated mass | 16.4 kDa from UniProt P02724; retain as context. |
| Gel selection | 15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A02184-2. |
| Situation | Likely cause | Next action |
|---|---|---|
| 16.4 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing GYPA band
A02184-2 · GYPAObserved 16.4 kDa · product-specific WB image
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Section 2
Real Curated GYPA Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Bone marrow |
| Gel % | 15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, short transfer |
| Membrane | 0.2 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A02184-2 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 4
Advanced GYPA Western Blot Tips
Deeper troubleshooting and optimisation questions for GYPA, answered from its protein features.
Which band should guide the blot?
Use 16.4 kDa, the observation attached to the authoritative A02184-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 16.4 kDa expectation.
Which positive control should I start with?
Start with Kidney, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Adipose tissue as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for GYPA Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A02184-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC3310074, PMC7075014.
Boster reagents
GYPA Western Blot Reagents
Human-reactive GYPA Western blot reagents with authoritative product imagery.
Real WB data
Anti-Glycophorin A/GYPA Antibody Picoband®
Cat # A02184-2
Reactivity: Human
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P02724
- Human Protein Atlas — GYPA
- A02184-2 product record
- PMC3310074 — Molecular characterisation of transport mechanisms at the developing mouse blood-CSF interface: a transcriptome approach.
- PMC7075014 — The histone methyltransferase Setd8 alters the chromatin landscape and regulates the expression of key transcription factors during erythroid differentiation.